jCell® Retinal Progenitor Cells (RPC) Restoring Vision in Patients with Blinding Diseases

John Sholar: A First-In-Class Revolutionary Platform. jCyte is about to begin its final trial of jCell, a cell therapy for the treatment of RP that has demonstrated restoration in vision for patients with sufficient remaining retinal tissue. Unlike gene therapies which target a specific genetic mutation, jCell is designed to treat RP regardless of the gene causing the disease. The treatment is dosed annually through an injection of a tiny amount of the drug into the eye using a well-established outpatient procedure. In five prior trials comprising 160 doses, jCell has been shown to be well tolerated and effective in patients with more than 8 degrees of visual field and sufficient remaining retinal tissue. A significant number of patients in those earlier trials had an Usher diagnosis. jCyte’s JC-03 study will enroll participants through multiple trial sites across the United States, but all dosing and efficacy visits will take place at the Gavin Herbert Eye Institute at the University of California, Irvine.